Piron B - Search Results

1

DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapy.

Piron B, Paillas S, Boudousq V, Pèlegrin A, Bascoul-Mollevi C, Chouin N, Navarro-Teulon I, Pouget JP. Piron B, et al. Nucl Med Biol. 2014 May;41 Suppl:e75-83. doi: 10.1016/j.nucmedbio.2014.01.012. Epub 2014 Feb 6. Nucl Med Biol. 2014. PMID: 24613681 Free article.

2

Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵I-labeled monoclonal antibodies targeting the cell membrane.

Paillas S, Boudousq V, Piron B, Kersual N, Bardiès M, Chouin N, Bascoul-Mollevi C, Arnaud FX, Pèlegrin A, Navarro-Teulon I, Pouget JP. Paillas S, et al. Among authors: piron b. Nucl Med Biol. 2013 May;40(4):471-80. doi: 10.1016/j.nucmedbio.2013.02.001. Epub 2013 Mar 19. Nucl Med Biol. 2013. PMID: 23522976 Free article.

3

From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience.

Pouget JP, Santoro L, Piron B, Paillas S, Ladjohounlou R, Pichard A, Poty S, Deshayes E, Constanzo J, Bardiès M. Pouget JP, et al. Among authors: piron b. Nucl Med Biol. 2022 Jan-Feb;104-105:53-64. doi: 10.1016/j.nucmedbio.2021.11.005. Epub 2021 Dec 6. Nucl Med Biol. 2022. PMID: 34922279 Review.

4

Determination of the lesion size in Laser-induced Interstitial Thermal Therapy (LITT) using a low-field MRI.

Viard R, Emptaz A, Piron B, Rochon P, Wassmer B, Mordon S. Viard R, et al. Among authors: piron b. Annu Int Conf IEEE Eng Med Biol Soc. 2007;2007:214-7. doi: 10.1109/IEMBS.2007.4352261. Annu Int Conf IEEE Eng Med Biol Soc. 2007. PMID: 18001927

5

Quad-class exposed/refractory myeloma is associated with short survival.

Piron B, Costes-Tertrais D, Gastinne T, Fourmont AM, Dubruille V, Blin N, Moreau P, Touzeau C, Tessoulin B. Piron B, et al. Br J Haematol. 2024 Jan;204(1):186-190. doi: 10.1111/bjh.19148. Epub 2023 Oct 13. Br J Haematol. 2024. PMID: 37833834

6

Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen.

Piron B, Bastien M, Antier C, Dalla-Torre R, Jamet B, Gastinne T, Dubruille V, Moreau P, Martin J, Bénichou A, Touzeau C, Tessoulin B. Piron B, et al. Haematologica. 2024 Jan 1;109(1):357-361. doi: 10.3324/haematol.2023.282919. Haematologica. 2024. PMID: 37470151 Free PMC article. No abstract available.

7

Failure to bispecific-antibody therapy is associated with a short survival in highly pre-treated patients with aggressive B-Cell Lymphomas.

Kevork K, Gouin M, Letailleur V, Chevallier P, Touzeau C, Gastinne T, Piron B, Tessoulin B. Kevork K, et al. Among authors: piron b. Curr Res Transl Med. 2023 Apr-Jun;71(2):103388. doi: 10.1016/j.retram.2023.103388. Epub 2023 Mar 26. Curr Res Transl Med. 2023. PMID: 37099834 No abstract available.

8

Assessment of combined use of ArcCheck^® detector and portal dosimetry for delivery quality assurance of head and neck and prostate volumetric-modulated arc therapy.

Moliner G, Sorro L, Verstraet R, Daviau PA, Casas M, Piron B, Dubois K, Debrigode C, Barrau C, Bons F, Greffier J. Moliner G, et al. Among authors: piron b. J Appl Clin Med Phys. 2018 Nov;19(6):133-139. doi: 10.1002/acm2.12460. Epub 2018 Oct 19. J Appl Clin Med Phys. 2018. PMID: 30338922 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters